American Screening Corp. Published July 15, 2026. Updated July 15, 2026.
A 12-panel cup covers the classic street and prescription drugs. A 14-panel adds two modern threats, most often fentanyl and either tramadol or EtG. An 18-panel adds the emerging analytes: xylazine, kratom, synthetic cannabinoids, and gabapentin. Choose based on what your population actually uses, not on strip count.
Panel inflation is real. More strips cost more money, and a strip for a drug your population never touches is money spent on nothing. This guide breaks down what each configuration typically contains, which additions are justified by the 2026 drug supply, and which industries need which panel.
What Is Actually in a 12, 14, and 18 Panel Cup?
Configurations vary by manufacturer, so always verify the strip list on the specific device. The table below shows typical builds.
| Analyte | 12-Panel | 14-Panel | 18-Panel |
|---|---|---|---|
| THC (marijuana) | Yes | Yes | Yes |
| COC (cocaine) | Yes | Yes | Yes |
| AMP (amphetamine) | Yes | Yes | Yes |
| mAMP (methamphetamine) | Yes | Yes | Yes |
| OPI (opiates/morphine) | Yes | Yes | Yes |
| OXY (oxycodone) | Yes | Yes | Yes |
| BZO (benzodiazepines) | Yes | Yes | Yes |
| BAR (barbiturates) | Yes | Yes | Yes |
| MTD (methadone) | Yes | Yes | Yes |
| MDMA (ecstasy) | Yes | Yes | Yes |
| PCP (phencyclidine) | Yes | Yes | Yes |
| BUP (buprenorphine) or TCA (tricyclics) | Yes | Yes | Yes |
| FYL (fentanyl) | No | Common | Yes |
| TRA (tramadol) or EtG (alcohol marker) | No | Common | Yes |
| XYL (xylazine) | No | No | Common |
| KRA/MIT (kratom/mitragynine) | No | No | Common |
| K2 (synthetic cannabinoids) | No | No | Common |
| GAB (gabapentin) | No | No | Common |
The first twelve rows are settled science and settled demand. The real 2026 decision is in the bottom six.
Does Your Panel Need Fentanyl in 2026?
For most programs, yes. Illegally made fentanyl remains the leading driver of US overdose deaths according to CDC overdose surveillance, and it does not reliably trigger the standard OPI (morphine) strip because fentanyl is a synthetic opioid with a different structure. A specimen can be loaded with fentanyl and still show OPI negative.
The federal government reached the same conclusion: HHS added fentanyl and norfentanyl to the federal workplace urine panel effective July 7, 2025 (90 FR 4662), and DOT has proposed adding both to 49 CFR Part 40 (90 FR 42363). If HHS considers fentanyl essential for federal employees, treatment centers, corrections, and staffing firms testing higher-risk populations should treat a FYL strip as baseline. This is the single strongest reason to step up from a legacy 12-panel to a 14-panel cup like the 14 panel urine drug test cup with fentanyl. Programs that want to keep their current cup can add fentanyl test strips alongside it.
What About Xylazine, Kratom, and Other Emerging Panels?
Xylazine (XYL). A veterinary sedative increasingly found mixed into illicit fentanyl. The DEA has publicly warned about the widespread threat of fentanyl mixed with xylazine, and the White House Office of National Drug Control Policy designated the combination an emerging threat on April 12, 2023. Xylazine is not an opioid, its effects are not reversed by naloxone, and no standard panel detects it. For treatment centers, harm reduction programs, and corrections in affected regions, an XYL strip answers a question nothing else on the cup can.
Kratom (KRA/MIT). Kratom's active alkaloid, mitragynine, acts on the same brain receptors as opioids according to the FDA, and kratom is legal in much of the country. It is invisible to every conventional opioid strip. Relevant for treatment and abstinence-monitoring programs where kratom use undermines recovery; rarely relevant for workplace programs.
Synthetic cannabinoids (K2). Useful in corrections and probation populations, where K2 use is common precisely because it evades the THC strip.
Gabapentin (GAB). Increasingly misused alongside opioids. Mostly relevant in clinical and treatment settings monitoring polysubstance use.
EtG. Not an emerging drug but an alcohol abstinence marker that extends detection well beyond breath or saliva alcohol testing. Standard in treatment and court programs where the sobriety requirement includes alcohol.
Which Panel Should Your Industry Choose?
| Buyer | Recommended Panel | Why |
|---|---|---|
| General workplace / staffing firms | 12-panel, or 14 with FYL | Core panel covers employment risk; fentanyl increasingly justified for safety-sensitive roles |
| Treatment centers / MAT programs | 14 to 18 panel with FYL and EtG | Relapse monitoring requires fentanyl, alcohol markers, and often kratom and gabapentin |
| Probation, parole, drug courts | 14 to 18 panel with FYL and K2 | Supervised populations shift to whatever the panel misses |
| Corrections facilities | 18-panel | Contraband markets favor K2, XYL-adulterated fentanyl, and novel substances |
| Pain management clinics | 12 to 14 panel with FYL | Adherence monitoring plus detection of illicit fentanyl substitution |
| Sober living homes | 14-panel with FYL and EtG | Alcohol and fentanyl are the two most common relapse vectors |
| DOT-regulated employers | Neither: use the DOT panel | DOT tests must follow 49 CFR Part 40 exactly; instant multi-panel cups are for non-DOT programs |
When Is a Bigger Panel a Waste of Money?
Three situations argue against paying for 18 strips:
- Low-risk employment screening. A professional services firm running pre-employment checks gains nothing from xylazine or kratom strips. A 12-panel, or a 14 with fentanyl, covers the realistic risk.
- DOT and other regulated testing. Regulated tests follow a fixed federal panel at a certified lab. Extra strips on an instant cup have no legal standing in that process.
- Populations you already know. If your program's confirmed positives over the past year are concentrated in five analytes, buying 18 every time is paying for information you already have. Many programs run a wide panel quarterly and a core panel for routine collections.
The per-unit price gap between configurations is modest at volume, but multiplied across thousands of collections a year it becomes a real budget line. Match the panel to the population, then buy that configuration in bulk. American Screening stocks every configuration discussed here, from standard multi-panel drug test cups up to the 18 panel drug test cup with adulterants for forensic programs.
Frequently Asked Questions
Does a 12-panel drug test detect fentanyl?
Usually not. Legacy 12-panel configurations predate the fentanyl era, and the OPI strip targets morphine-class opiates, which fentanyl is not. If fentanyl detection matters to your program, choose a cup that explicitly lists a FYL strip or add fentanyl test strips alongside your current cup.
What is the difference between a 14-panel and an 18-panel cup?
Typically four strips. A common 14-panel is the standard 12 drugs plus fentanyl and one other analyte such as tramadol or EtG. An 18-panel adds emerging substances, commonly xylazine, kratom (mitragynine), synthetic cannabinoids (K2), and gabapentin. Exact configurations vary by manufacturer, so check the product specification.
Are instant multi-panel cups as accurate as lab tests?
Instant cups are screening devices calibrated to standard cutoffs, and quality devices perform well at that job. They are presumptive by design. Any non-negative result that will drive a consequence, whether clinical, employment, or legal, should be confirmed by GC-MS or LC-MS/MS at a laboratory.
Can I use an 18-panel cup for DOT testing?
No. DOT testing must follow 49 CFR Part 40: a fixed analyte panel, collection on a federal CCF, analysis at an HHS-certified laboratory, and MRO review. Instant cups of any panel size are for non-regulated programs only.
Do xylazine test strips detect fentanyl too?
No. Each strip on a panel detects only its target analyte. Xylazine is commonly mixed with fentanyl in the illicit supply, which is exactly why programs concerned about it run FYL and XYL strips together.
Sources
- HHS Mandatory Guidelines, Authorized Testing Panels, 90 FR 4662 (Jan. 16, 2025, effective July 7, 2025): https://www.federalregister.gov/documents/2025/01/16/2025-00425/mandatory-guidelines-for-federal-workplace-drug-testing-programs-authorized-testing-panels
- HHS Mandatory Guidelines, Authorized Testing Panels, 91 FR 12308 (Mar. 13, 2026): https://www.federalregister.gov/documents/2026/03/13/2026-04981/mandatory-guidelines-for-federal-workplace-drug-testing-programs-authorized-testing-panels
- DOT NPRM adding fentanyl to the DOT panel, 90 FR 42363 (Sept. 2, 2025): https://www.federalregister.gov/documents/2025/09/02/2025-16720/procedures-for-transportation-workplace-drug-and-alcohol-testing-programs-addition-of-fentanyl-to
- CDC, Understanding the Opioid Overdose Epidemic: https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
- DEA, Public Safety Alert on Fentanyl Mixed with Xylazine: https://www.dea.gov/alert/dea-reports-widespread-threat-fentanyl-mixed-xylazine
- ONDCP, Emerging Threat Designation for Fentanyl Combined with Xylazine (Apr. 12, 2023): https://bidenwhitehouse.archives.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/
- FDA, FDA and Kratom: https://www.fda.gov/news-events/public-health-focus/fda-and-kratom
- 49 CFR Part 40: https://www.ecfr.gov/current/title-49/subtitle-A/part-40
